Who is eligible for clinical trial NCT01902576?

Participants must meet protocol criteria for Graft vs Host Disease. Confirm exact inclusion and exclusion requirements with the study coordinator.

Does clinical trial NCT01902576 provide travel or cost reimbursement?

Check with the site coordinator at the participating facility for travel and lodging stipend availability, and for which routine-care costs are covered.

🏛️ Verified NIH Record • Updated 2026-03-18

Chronic GVHD Response Measures Validation (NCT01902576)

🔵 Active, Not Recruiting Interventional Protocol 📊 Observational Clinical Research Sponsor: Fred Hutchinson Cancer Center

🩺 Plain-English Summary (8th-Grade Level)

The purpose of this study is to develop and validate endpoint measures that can accurately determine whether patients are responding to treatment for chronic Graft-versus-Host Disease (GVHD). Hopefully, this will also lead to being better able to predict which patients will respond to what therapies.

Who can join: To join this study, participants generally need to meet the listed inclusion criteria (7 items) and avoid the listed exclusions (3 items).

Location: Fred Hutchinson Cancer Research Center — Seattle, Washington

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

Age 7 years or older
Prior first allogeneic stem cell transplant, with any graft source, donor type, and GVHD prophylaxis.
Diagnosis of chronic GVHD according to the criteria of the diagnosis and scoring group of the NIH consensus conference (Patient must have at least one diagnostic manifestation of chronic GVHD or one distinctive manifestation with pathological confirmation of the diagnosis. Concurrent acute GVHD manifestations will be allowed as long as at least one classic chronic manifestation is present.)
Initiation of a new systemic treatment for chronic GVHD in the past 4 weeks or anticipated within the next 4 weeks. Systemic treatment is defined as any medication or intervention that has intended systemic effects, including extracorporeal photopheresis, regardless of prior lines of therapy or prior treatment with the agent(s). If a patient is restarting a treatment to which they were previously exposed, they must have been off of it for at least 4 weeks before restarting.
No evidence of persistent or progressive malignancy at the time of enrollment
Evaluation at the transplant center at the time of study enrollment, and agreement to be re-evaluated at the transplant center up to four subsequent times: at 3 months, 6 months, and 18 months after enrollment and once if another treatment is added for chronic GVHD.
Signed, informed consent

Usually NOT eligible if any of the following apply:

Exclusion Criteria:
Inability to comply with study procedures
Complete resolution of chronic GVHD at the time of enrollment (patient must have some measurable chronic GVHD activity)

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (1 Sites)

Fred Hutchinson Cancer Research Center — Seattle, Washington

💰 Cost, Insurance & Patient Rights

100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

🏛️ View Official NIH Record ↗